menu
    • menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hildred Capital Management, LLC, Bourne Partners Strategic Capital and The Emerson Group Launch Carlin Consumer Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Carlin Consumer Health","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Carlin Consumer Health"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep\u2122 (Omeprazole and Sodium Bicarbonate for Oral Suspension)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole","moa":"ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Active Benign Gastric Ulcer and Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole","moa":"KATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Brand Institute","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Brand Institute \/ Azurity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Brand Institute \/ Azurity Pharmaceuticals"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia\u00ae with IP Protection Running to 2034","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Amoxicillin Trihydrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talicia\u00ae Launched in the United Arab Emirates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Amoxicillin Trihydrate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"RedHill Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000493

    Menu

    Prestwick3_000493

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RedHill Biopharma

                            Israel arrow
                            AAPS 2024
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amoxicillin Trihydrate,Rifabutin,Omeprazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Talicia® Launched in the United Arab Emirates

                            Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.

                            Brand Name : Talicia

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 21, 2024

                            Lead Product(s) : Amoxicillin Trihydrate,Rifabutin,Omeprazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RedHill Biopharma

                            Israel arrow
                            AAPS 2024
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amoxicillin Trihydrate,Rifabutin,Omeprazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Runni...

                            Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.

                            Brand Name : Talicia

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : Amoxicillin Trihydrate,Rifabutin,Omeprazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Brand Institute

                            Country arrow
                            AAPS 2024
                            Not Confirmed

                            Brand Institute

                            Country arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Azurity Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Active Benign Gastric Ulcer ...

                            Details : KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients...

                            Brand Name : Konvomep

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Azurity Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Azurity Pharma

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep™ (Omeprazole and Sodium Bicarbonate for Ora...

                            Details : Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.

                            Brand Name : Konvomep

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 02, 2022

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bayer AG

                            Germany arrow
                            AAPS 2024
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Carlin Consumer Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Hildred Capital Management, LLC, Bourne Partners Strategic Capital and The Emerson Group Launch Carlin Consume...

                            Details : Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.

                            Brand Name : Zegerid

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 01, 2022

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Carlin Consumer Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth